Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)

GG Steger; Richard Greil; R Jakesz; A Lang; Brigitte Mlineritsch; M Rudas; C Marth; H Stoeger; CF Singer; M Gnant

doi:10.1016/S1359-6349(10)70040-9

Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)

GG Steger, Richard Greil, R Jakesz, A Lang, Brigitte Mlineritsch, M Rudas, C Marth, H Stoeger, CF Singer, M Gnant

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	60-60
Journal	ECJ SUPPLEMENTS
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/S1359-6349(10)70040-9
Publication status	Published - 2010
Event	European Breast Cancer Conference - Barcelona, SPAIN Duration: 24 Mar 2010 → 24 Mar 2010

Access to Document

10.1016/S1359-6349(10)70040-9

Cite this

Steger, GG., Greil, R., Jakesz, R., Lang, A., Mlineritsch, B., Rudas, M., Marth, C., Stoeger, H., Singer, CF., & Gnant, M. (2010). Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). ECJ SUPPLEMENTS, 8(3), 60-60. https://doi.org/10.1016/S1359-6349(10)70040-9

@article{027774cdee79497082490f9d3fa19c60,

title = "Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)",

author = "GG Steger and Richard Greil and R Jakesz and A Lang and Brigitte Mlineritsch and M Rudas and C Marth and H Stoeger and CF Singer and M Gnant",

year = "2010",

doi = "10.1016/S1359-6349(10)70040-9",

language = "English",

volume = "8",

pages = "60--60",

journal = "ECJ SUPPLEMENTS",

issn = "1359-6349",

number = "3",

note = "European Breast Cancer Conference ; Conference date: 24-03-2010 Through 24-03-2010",

}

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Rudas, M, Marth, C, Stoeger, H, Singer, CF & Gnant, M 2010, 'Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)', ECJ SUPPLEMENTS, vol. 8, no. 3, pp. 60-60. https://doi.org/10.1016/S1359-6349(10)70040-9

Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). / Steger, GG; Greil, Richard; Jakesz, R et al.
In: ECJ SUPPLEMENTS, Vol. 8, No. 3, 2010, p. 60-60.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)

AU - Steger, GG

AU - Greil, Richard

AU - Jakesz, R

AU - Lang, A

AU - Mlineritsch, Brigitte

AU - Rudas, M

AU - Marth, C

AU - Stoeger, H

AU - Singer, CF

AU - Gnant, M

PY - 2010

Y1 - 2010

U2 - 10.1016/S1359-6349(10)70040-9

DO - 10.1016/S1359-6349(10)70040-9

M3 - Abstract (Journal)

SN - 1359-6349

VL - 8

SP - 60

EP - 60

JO - ECJ SUPPLEMENTS

JF - ECJ SUPPLEMENTS

IS - 3

T2 - European Breast Cancer Conference

Y2 - 24 March 2010 through 24 March 2010

ER -